Clinical

Dataset Information

0

Phase II study of PM60184 in patients with advanced colon-rectal cancer after standard treatment.


ABSTRACT: Primary objectives: To evaluate the efficacy of PM060184 in terms ofprogression-free survival at 12 weeks (PFS3) in patients withadvanced colorectal carcinoma (CRC) after standard therapy. Primary endpoints: PFS3, defined as the percentage of patients remaining aliveand progression-free at Week 12 (Month 3) after the firsttreatment dose.

DISEASE(S): Cáncer Colorectal Avanzado,Colorectal Cancer,Advanced Colorectal Cancer

PROVIDER: 2536604 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2013-12-13 | GSE46646 | GEO
2024-11-05 | GSE237747 | GEO
2024-11-05 | GSE237743 | GEO
2024-11-05 | GSE237737 | GEO
2013-12-13 | E-GEOD-46646 | biostudies-arrayexpress
2011-12-20 | E-GEOD-34472 | biostudies-arrayexpress
2011-12-20 | GSE34472 | GEO
| PRJNA541284 | ENA
| PRJNA1311520 | ENA
2022-12-31 | GSE200612 | GEO